Back to discover

Protein / target

Neurogranin

Encoded byNRGNQ92686Homo sapiensSwiss-Prot
UniProt: Q92686Ensembl: ENSG00000154146HGNC: HGNC:8000NCBI Gene: 4900
Degrader-tractable
Druggability
Half-life Data
2
Research papers

Protein at a glance

Biological role

Phosphatidylinositol-3,4,5-trisphosphate binding

Strongest disease association

Schizophrenia

Via encoding gene NRGN · Genetic evidence · score 0.67

Research activity

Emerging research

2 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Acts as a 'third messenger' substrate of protein kinase C-mediated molecular cascades during synaptic development and remodeling.

View complete UniProt function annotation

Acts as a 'third messenger' substrate of protein kinase C-mediated molecular cascades during synaptic development and remodeling. Binds to calmodulin in the absence of calcium (By similarity)

Domains and Gene Ontology detail (19)

Domains & features

IQCollagen-like

Gene Ontology

  • Caxon
  • Ccytosol
  • Cdendritic spine head
  • Cglutamatergic synapse
  • Cmitochondrial membrane
  • Cneuronal cell body
  • Cpostsynaptic membrane
  • Ctrans-Golgi network transport vesicle membrane
  • Fcalmodulin binding
  • Fphosphatidic acid binding
  • Fphosphatidylinositol-3,4,5-trisphosphate binding
  • Passociative learning

78 aa · 8 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Synaptic signallingGO
View supporting evidence

Synaptic signalling

  • ·glutamatergic synapse
  • ·postsynaptic membrane
  • ·postsynaptic modulation of chemical synaptic transmission

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene NRGN

Gene-level evidence surfaced through the gene NRGNthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Schizophrenia
0.70Moderately supported

Genetic evidence dominant · Open Targets 0.43

Smoking initiation
0.59Moderately supported

Genetic evidence dominant · Open Targets 0.36

Attention Deficit Disorder with Hyperactivity
0.57Moderately supported

Genetic evidence dominant · Open Targets 0.35

Autism Spectrum Disorder
0.49Limited support

Genetic evidence dominant · Open Targets 0.30

Substance-Related Disorders
0.47Limited support

Genetic evidence dominant · Open Targets 0.29

View evidence synthesis (5)
SchizophreniaModerately supported
0.70
agreement 0.56–0.84
Genetic87%Literature13%

Open Targets aggregate 0.43 · 2 independent evidence families

Smoking initiationModerately supported
0.59
agreement 0.47–0.71
Genetic100%

Open Targets aggregate 0.36 · 1 independent evidence family

Attention Deficit Disorder with HyperactivityModerately supported
0.57
agreement 0.43–0.71
Genetic97%Literature3%

Open Targets aggregate 0.35 · 2 independent evidence families

Autism Spectrum DisorderLimited support
0.49
agreement 0.35–0.63
Genetic99%Literature1%

Open Targets aggregate 0.30 · 2 independent evidence families

Substance-Related DisordersLimited support
0.47
agreement 0.35–0.59
Genetic100%

Open Targets aggregate 0.29 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neurodegenerative Diseases0.44
Schizophrenia0.43
Smoking initiation0.36
Attention Deficit Disorder with Hyperactivity0.35
Autism Spectrum Disorder0.30
Substance-Related Disorders0.29
Major depressive disorder0.25
Bipolar Disorder0.24
Obsessive-Compulsive Disorder0.24
Intelligence0.24

Tractability

Protein degraders — Emerging

Feasibility evidence (half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (1)
PR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Delivering synaptic protein mRNAs via extracellular vesicles ameliorates cognitive impairment in a mouse model of Alzheimer's disease.19 cites

Cai H · BMC medicine · 2024

The Relationships between Cerebrospinal Fluid Glial (CXCL12, CX3CL, YKL-40) and Synaptic Biomarkers (Ng, NPTXR) in Early Alzheimer's Disease.10 cites

Kulczyńska-Przybik A · International journal of molecular sciences · 2023

Recent

Delivering synaptic protein mRNAs via extracellular vesicles ameliorates cognitive impairment in a mouse model of Alzheimer's disease.

Cai H · BMC medicine · 2024

The Relationships between Cerebrospinal Fluid Glial (CXCL12, CX3CL, YKL-40) and Synaptic Biomarkers (Ng, NPTXR) in Early Alzheimer's Disease.

Kulczyńska-Przybik A · International journal of molecular sciences · 2023

Europe PMC papers linked directly to this protein.